skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Tolvaptan, hyponatremia, and heart failure

Review

(2196) Views  (684) Full article downloads

Authors: Zmily HD, Daifallah S, Ghali JK

Published Date March 2011 Volume 2011:4 Pages 57 - 71
DOI: http://dx.doi.org/10.2147/IJNRD.S7032

Hammam D Zmily1, Suleiman Daifallah2, Jalal K Ghali3
1Wayne State University/Detroit Medical Center, Detroit, MI, USA; 2John D Dingell VA Medical Center, Detroit, MI, USA; 3Detroit Medical Center, Detroit, MI, USA

Abstract: Tolvaptan is the first FDA-approved oral V2 receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan inhibits the binding of arginine vasopressin to the V2 receptors on the collecting ducts of the kidneys resulting in aquaresis, the electrolytes sparing excretion of water. This article reviews the accumulated experience with tolvaptan and all the major clinical trials that were conducted to study its safety and efficacy and concludes by summarizing clinicians’ views of its current application in clinical practice.

Keywords: arginine vasopressin antagonist, tolvaptan, heart failure, hyponatremia

 






 

Other articles by Dr Jalal Ghali



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Diabetic microvascular complications: possible targets for improved macrovascular outcomes
Erratum - Intracellular heavy metal nanoparticle storage
Contrast-induced nephropathy in interventional cardiology
Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism
Kidney function and mortality post-liver transplant in the Model for End-Stage Liver Disease era
Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis
Functional evaluation of the urinary tract by duplex Doppler ultrasonography in patients with acute renal colic
Emerging drug combinations to optimize renovascular protection and blood pressure goals
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio